Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes

- Treatment with Bristol Myers Squibb's immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the drugs before node removal procedures, according to data from a late-stage trial released on Sunday.The study of 423 patients with stage 3 melanoma found that 83.7% of patients who received the immunotherapies before their surgery were alive without the disease worsening after 12-months.

The 12-month event-free survival rate in the patients who did not receive the so-called neoadjuvant treatment, but were treated with Opdivo for a year afterward, was 57.2%, researchers reported at the American Society of Clinical Oncology meeting in Chicago. Around 58% of patients in the treatment arm had a complete pathologic response, meaning there was no sign of cancer in the removed lymph nodes, and they did not receive additional treatment.

The rest of the patients either received more Opdivo or Novartis' targeted drugs Tafinlar and Mekinist."Many patients can just be treated with a very limited course, albeit it has a little more toxicity, but not have to complete a whole year... That's a really good outcome," she said. The study was sponsored by the Netherlands Cancer Institute and the Melanoma Institute Australia and funded by Bristol Myers Squibb and the National Health and Medical Research Council Australia.It has been our privilege to have the trust and support of our East Coast communities for the last 200 years. Our SaltWire team is always watching out for the place we call home.

Source: Healthcare Press (healthcarepress.net)

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomesExplore stories from Atlantic Canada.
Source: SaltWire Network - 🏆 45. / 63 Read more »

Bristol-Meyers Squibb sunk S&P 500 this earnings season: FactSetMore than 90% of the companies in the S&P 500 (^GSPC) have reported their earnings for the first quarter of 2024, which yielded a mostly strong result for...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

Bristol’s $250,000 Pill Slows Lung Cancer Growth by Seven WeeksA Bristol Myers Squibb Co. lung cancer treatment delayed tumor growth by less than seven weeks in a closely watched clinical trial, a disappointing result after the company paid nearly $5 billion to acquire the drug’s owner.
Source: BNNBloomberg - 🏆 83. / 50 Read more »

Calgarians shine a light on Parkinson’s as researchers explore new therapiesA Calgary mother and daughter share a deep bond as they gather at an inaugural Parkinson's Disease picnic shining a light on Canada's fastest growing neurological disease.
Source: GlobalCalgary - 🏆 50. / 61 Read more »

Five Ontario cities were just crowned the best in Canada for tourists to explore on footOntario locales dominate a new ranking of the most pedestrian-friendly cities in Canada for tourists, claiming five of the top ten spots in the stu...
Source: blogTO - 🏆 44. / 63 Read more »

Vancouver to explore conversion of office space to ‘pod hotels’The pod hotel concept, which originated in Japan, features small, bed-sized rooms that offer cheaper, basic overnight accommodations.
Source: GlobalCalgary - 🏆 50. / 61 Read more »